646 related articles for article (PubMed ID: 28004184)
21. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
[TBL] [Abstract][Full Text] [Related]
22. Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial.
Truong QA; Siegel E; Karakas M; Januzzi JL; Bamberg F; Mahabadi AA; Dasdemir S; Brady TJ; Bergmann A; Kunde J; Nagurney JT; Hoffmann U; Koenig W
Clin Chem; 2010 Apr; 56(4):651-60. PubMed ID: 20185624
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
[TBL] [Abstract][Full Text] [Related]
24. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study.
Ndumele CE; Matsushita K; Sang Y; Lazo M; Agarwal SK; Nambi V; Deswal A; Blumenthal RS; Ballantyne CM; Coresh J; Selvin E
Circulation; 2016 Feb; 133(7):631-8. PubMed ID: 26746175
[TBL] [Abstract][Full Text] [Related]
25. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
26. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP.
Gegenhuber A; Struck J; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
Clin Chem; 2006 May; 52(5):827-31. PubMed ID: 16543387
[TBL] [Abstract][Full Text] [Related]
27. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.
Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M
Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
29. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure.
Tan ESJ; Chan SP; Liew OW; Chong JPC; Gerard Leong KT; Daniel Yeo PS; Ong HY; Jaufeerally F; Sim D; Ling LH; Lam CSP; Richards AM
JACC Heart Fail; 2024 Mar; 12(3):461-474. PubMed ID: 37897459
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based prospective study.
Holm H; Nägga K; Nilsson ED; Ricci F; Melander O; Hansson O; Bachus E; Magnusson M; Fedorowski A
J Intern Med; 2017 Jul; 282(1):94-101. PubMed ID: 28407377
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
[TBL] [Abstract][Full Text] [Related]
32. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
33. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
[TBL] [Abstract][Full Text] [Related]
34. Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD).
Claus R; Berliner D; Bavendiek U; Vodovar N; Lichtinghagen R; David S; Patecki M; Launay JM; Bauersachs J; Haller H; Hiss M; Balzer MS
Clin Res Cardiol; 2020 Aug; 109(8):1035-1047. PubMed ID: 32002632
[TBL] [Abstract][Full Text] [Related]
35. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
[TBL] [Abstract][Full Text] [Related]
36. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).
Bhatt AS; Cooper LB; Ambrosy AP; Clare RM; Coles A; Joyce E; Krishnamoorthy A; Butler J; Felker GM; Ezekowitz JA; Armstrong PW; Hernandez AF; O'Connor CM; Mentz RJ
J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29431103
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers and diagnostics in heart failure.
Gaggin HK; Januzzi JL
Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
[TBL] [Abstract][Full Text] [Related]
38. Mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in severe aortic valve stenosis: association with outcome after transcatheter aortic valve implantation (TAVI).
Baldenhofer G; Laule M; Mockel M; Sanad W; Knebel F; Dreger H; Leonhardt F; Sander M; Grubitzsch H; Baumann G; Stangl K; Stangl V
Clin Chem Lab Med; 2017 Feb; 55(2):275-283. PubMed ID: 27522619
[TBL] [Abstract][Full Text] [Related]
39. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure.
Li J; Cui Y; Huang A; Li Q; Jia W; Liu K; Qi X
Med Sci Monit; 2018 Jul; 24():4992-4999. PubMed ID: 30019695
[TBL] [Abstract][Full Text] [Related]
40. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
